Getty Images Listen below or on the go via Apple Podcasts and Spotify The director for the Center for Drug Evaluation and Research was accused of making false statements about a drug and soliciting a bribe. (0:15) Baidu’s Apollo Go hits driverless ride landmark. (1:20) Trump says only U.S. will get access to Nvidia’s Blackwell line. (2:08) The following is an abridged transcript: George Tidmarsh is out as director of the FDA’s Center for Drug Evaluation and Research amid accusations that he made fal ...

Group 1: FDA and Aurinia Pharmaceuticals - George Tidmarsh has resigned as director of the FDA's Center for Drug Evaluation and Research amid accusations of making false statements about Aurinia Pharmaceuticals' lupus nephritis treatment and soliciting a bribe [4][3] - Aurinia Pharmaceuticals has filed a federal lawsuit against Tidmarsh, claiming he made false statements and sought a bribe in retaliation against its chairman, Kevin Tang [4] - Tidmarsh criticized the FDA's new National Priority Review Voucher program, suggesting it could alter drug approval processes without adequate legal support [4] Group 2: Autonomous Driving - Baidu's Apollo Go unit has achieved a milestone of over 250,000 fully driverless rides per week as of October 31, matching the weekly rides reported by Waymo [5] - The total number of robotaxi rides operated by Apollo Go during the quarter ending June 30 was 2.2 million, averaging around 169,000 rides per week [6] Group 3: Nvidia and U.S. Market - President Trump announced that Nvidia's most advanced Blackwell chips will be exclusively available to U.S. companies, restricting access to other countries [7]

BioNTech raised its sales forecast for the year, helped by a boost from its partnership with Bristol-Myers Squibb https://t.co/0ZVQtxHGor ...

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. Accessibility StatementSkip Navigat ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Gaithersburg, Maryland--(Newsfile Corp. - November 3, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced that it entered into a securities purchase agreement with a single investor for aggregate gross proceeds of approximately $2.5 million (the "Offering"), before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for marketing, general corpora ...

WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that David Amsellem, Sr. Research Analyst at Piper Sandler, will host a live fireside chat with the Company’s management team on November 6, 2025 at 12:00 p.m. ET. The discussion will focus on the Company’s product candida ...

Accessibility StatementSkip Navigation Endometrial Cancer – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – –Â Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Â Conference Call Scheduled for Today at 8:00 ...

CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA. Details of presentation: Format: Fireside chat Participants: Chris Giordano, Presiden ...

Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda. ...